| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 41,032 | 42,988 | ||
| Short-term investments | 229,176 | 132,915 | ||
| Other current assets (including 177 and 0 as of september 30, 2025 and december 31, 2024, respectively, from a related party) | 11,149 | 10,663 | ||
| Total current assets | 281,357 | 186,566 | ||
| Long-term investments | 0 | 0 | ||
| Property and equipment, net | 2,826 | 2,988 | ||
| Operating lease right-of-use assets | 7,171 | 7,585 | ||
| Equity method investment in gannet biochem | 4,837 | 5,371 | ||
| Other assets | 5,156 | 5,024 | ||
| Total assets | 301,347 | 207,534 | ||
| Accounts payable | 15,563 | 14,281 | ||
| Accrued expenses (including 316 and 3,403 as of september 30, 2025 and december 31, 2024, respectively, to a related party) | 28,594 | 35,099 | ||
| Operating lease liabilities, current portion | 22,183 | 22,011 | ||
| Total current liabilities | 66,340 | 71,391 | ||
| Operating lease liabilities, less current portion | 69,732 | 74,145 | ||
| Liabilities related to the sales of future royalties, net | 75,164 | 80,573 | ||
| Other long-term liabilities | 5,025 | 5,636 | ||
| Total liabilities | 216,261 | 231,745 | ||
| Common stock, 0.0001 par value 390,000,000 shares and 300,000,000 shares authorized at september 30, 2025 and december 31, 2024 19,652,513 shares and 12,937,308 shares issued at september 30, 2025 and december 31, 2024, respectively 19,652,513 shares and 12,385,001 shares outstanding at september 30, 2025 and december 31, 2024, respectively | 2 | 1 | ||
| Capital in excess of par value | 3,809,235 | 3,667,487 | ||
| Treasury stock, at cost 0 shares and 552,307 shares as of september 30, 2025 and december 31, 2024, respectively | 0 | 3,000 | ||
| Accumulated other comprehensive income (loss) | 56 | -14 | ||
| Accumulated deficit | -3,724,207 | -3,688,685 | ||
| Total stockholders' equity | 85,086 | -24,211 | ||
| Total liabilities and stockholders' equity | 301,347 | 207,534 | ||
NEKTAR THERAPEUTICS (NKTR)
NEKTAR THERAPEUTICS (NKTR)